NCT07221981Completed
Study of Patient With Frequent COPD Exacerbations
Clinical and dEmographic chaRacteristics of Patients With Frequent COPD Exacerbations and Evaluation of Therapeutic Approaches in Treatment in RussiA
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent exacerbations in the Russian Federation. Planned number of Study site is 35 outpatient centers with experience of treatment of COPD with frequency exacerbations in about 30 regions in Russia.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2024 (actual)
- First submitted
- 13 May 2025
- Start date
- 16 Dec 2024
- Primary completion date
- 22 Jun 2026
- Lead sponsor
- AstraZeneca
- Diseases
- COPD
- NCT number
- NCT07221981
What you commit to
- Study type: Observational
- Participants enrolled: 2024
- From 16 Dec 2024 to the primary completion date, 22 Jun 2026
- 30 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous treatment with triple combination (ICS/LABA/LAMA) within 52 weeks prior to inclusion;
- The participation in any clinical study currently or within 52 weeks prior to inclusion.
Other illness
- A diagnosis of bronchiectasis, sarcoidosis, interstitial lung diseases, or idiopathic pulmonary fibrosis, exacerbation of bronchial asthma or any acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results;
Other
- COPD due to documented α-1 antitrypsin deficiency;
Who the study is looking for
- Age ≥ 18 years at the time of inclusion;
- Signed and dated written informed consent in accordance with ICH-GCP and local law prior to inclusion in the study;
- Patients with diagnosed moderate-to-severe COPD (see comments below);
- ≥2 moderate or ≥1 severe COPD exacerbations in previous 52 weeks (see comments below);
- Patients have been receiving two inhaled maintenance therapies (LABA/LAMA, ICS/LABA, ICS/LAMA) for at least 6 weeks prior to inclusion.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (30)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.